Heavy Guide, New Drug Show, UKPDS - 2022 EASD Annual Meeting is coming, four highlights to see first! 2022EASD

Edited and written by Yimaitong, please do not reprint

Introduction: From September 19 to 23, 2022, the annual endocrine academic feast - the 58th Annual Conference (EASD) of the European Association for Diabetes Research in 2022 will be held in Stockholm, Sweden, which will be the first "face-to-face" meeting since 2019, and the content of the conference will be transmitted to the world in the

Taking over the ADA and ENDO that have just ended in June, what will be the highlights of this EASD? According to the official announcement, Xiaobian summarized the four highlights of this conference and shared

Joint ADA/EASD 2022: Type 2 Diabetes Hyperglycemia Management is coming soon!

On September 23, the final content of the "2022ADA/EASD Joint Consensus: Management of Hyperglycemia in Type 2 Diabetes" is undoubtedly the most important academic content

In June this year, the "2022ADA/EASD Joint Consensus: Type 2 Diabetes Hyperglycemia Management (Draft)" was released and solicited for comments at the 82nd American Diabetes Association Scientific Conference (ADA), which was reported for the first time by Yimaitong, of which "emphasizing weight loss" and "changes in the drug recommendation roadmap" were the main update highlights

According to some scholars, the revised ADA/EASD consensus is expected to support weight loss as a "main common goal" in the care of patients with acardial kidney disease, while recommending starting combination therapy as early as possible rather than the previous gradual combination: for example, taking two drugs immediately after diagnosis, rather than just metformin

Draft review

1.

Type 2 diabetes is closely linked to obesity, with an estimated 1 billion people worldwide suffering from obesity by 2030

➤ Weight loss should be considered as a therapeutic strategy to improve glycemic control and reduce the risk of weight-related complications;

➤ Recent evidence suggests that for some patients with type 2 diabetes, weight loss of 5% to 15% should be the primary goal of treatment;

➤ The greater the magnitude of weight loss, the greater the possible benefit: weight loss of 5%-10% can improve metabolic status, weight loss of 10%-15% or more can improve the disease, and even bring diabetes relief;

➤ Weight loss may bring benefits beyond glycemic control, thereby improving risk factors and quality

2.

The "Recommended Roadmap for Type 2 Diabetes Management Drugs" in the new version of the consensus (draft) has changed significantly, and according to the characteristics of the patient's own disease, different "treatment goals" have been recommended:

➤ Treatment goal 1: Type 2 diabetes mellitus with high risk of heart and kidneys, with the goal of "reducing the risk of adverse events in the heart and kidneys";

➤Treatment goal 2: People with type 2 diabetes who

Figure 1 Recommended drug pathway for type 2 diabetes management (draft)

A milestone in diabetes research – UKPDS 44 years of data coming soon!

The UK Prospective Diabetes Study (UKPDS) is a multicentre, randomised controlled study
of different treatments for type 2 diabetes completed in the UK.

The study, which began in 1977 and ended in 1997, lasted 20 years, included 5102 newly diagnosed patients with type 2 diabetes, with a median follow-up time of more than 10 years, and is a landmark study
in the treatment of type 2 diabetes.

The main objective of UKPDS is to study the effects of enhanced blood glucose and blood pressure control on the development of chronic complications in patients with type 2 diabetes, and to compare the roles
of different hypoglycemic measures in blood glucose control and the prevention and treatment of chronic complications in patients with type 2 diabetes.

The results of randomized controlled trials published in 1998 and 2000 and epidemiological observational studies showed that strict control of blood glucose can reduce the occurrence of microvascular disease, and observational studies have shown that strict control of blood sugar can also reduce the occurrence
of cardiovascular complications.

On 21 September, in the UKPDS 44-Year Follow-up Symposium section of the EASD Conference, researchers will present 44 years of data from UKPDS, on topics such as "Is the legacy effect sustainable?", "Economic analysis of lifetime outcomes of UKPDS treatment policies", and "The impact of UKPDS treatment policies on dementia prognosis"
.

Dapagliflozin and Heart Failure Treatment – The latest results of the DELIVER trial will be announced soon!

On September 22, the latest data from the DELIVER trial, presented at this EASD conference, will bring us the latest research advances in the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin in heart failure patients with ejection fraction retention (compared in patients with diabetes, prediabetes and normal blood glucose).

On August 26, the preliminary results of the DELIVER trial were presented at the 2022 European Society of Cardiology (ESC) Conference in Barcelona, Spain, and published simultaneously in the New England Journal of Medicine
.

The results showed that dapagliflozin also benefited patients with heart failure who retained ejection fraction, and also aroused great interest
in the field of diabetes treatment.

The double benefits of weight loss and sugar reduction - the latest data of GLP-1/GIP bi-agonist Tirzepatide will be released soon!

On September 21, the EASD Conference will publish the latest research data on the
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin polypeptide (GIP) bi-agonist tirzepatide.

The drug was approved in the United States in May 2022 for the treatment of type 2 diabetes
.

Currently, people are studying this drug as a drug for treating obesity
.

Data from the SURMOUNT-1 trial, released at the ADA conference in June, showed that the drug had an "unprecedented" weight loss effect, with a weight loss effect of up to 22.
5%.


At this session of the EASD conference, these findings will be reviewed and new data on morbidity and mortality will be presented
for the first time.